Oxidative stress as a cofactor in spinocerebellar ataxia type 2

Redox Report

Volumn 17, Issue 2, 2012, Pages 84-89

  Guevara García, Mariela ^a   Valle, Lizette Gil Del ^b   Velásquez Pérez, Luis ^c,e   García Rodríguez, Julio César ^d  

^a Research and Development Department   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^c Centro para la Investigacion y Rehabilitacion de las Ataxias Hereditarias Cuba   (Cuba)

^d National Center for Animal Breeding (CENPALAB)   (Cuba)

^e NONE   (Cuba)

Author keywords

Ataxine 2; Neurodegenerative; Oxidative stress; Redox markers; Spinocerebellar ataxia

Indexed keywords

ATAXIN 1; ATAXIN 17; ATAXIN 2; ATAXIN 3; ATAXIN 6; ENDOPHILIN A1; ENDOPHILIN A3; FRATAXIN; LACTIC ACID; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG; ZINC; ZINC SULFATE;

ANHIDROSIS; ATAXIA; ATAXIA TELANGIECTASIA; AUSTRALIA; AXONAL INJURY; CAG REPEAT; CEREBROSPINAL FLUID; CHROMOSOME 12; CLINICAL FEATURE; COGNITIVE DEFECT; CONSTIPATION; CUBA; CYTOPLASM; DEMYELINATION; DYSARTHRIA; DYSDIADOCHOKINESIA; DYSMETRIA; DYSPHAGIA; ENDOCYTOSIS; EYE MOVEMENT DISORDER; FRIEDREICH ATAXIA; GAIT DISORDER; GENE FREQUENCY; GENE MUTATION; GERMANY; HEREDITARY ATAXIA; HUMAN; INCIDENCE; INDIA; ITALY; MARTINIQUE; MEXICO; MITOCHONDRION; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; MYOCLONUS EPILEPSY; NEUROTOXICITY; OXIDATIVE STRESS; PALLIATIVE THERAPY; PARKINSONISM; PATHOGENESIS; PERIPHERAL NEUROPATHY; POINT MUTATION; POLAND; POLYSOME; PORTUGAL; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINITIS PIGMENTOSA; REVIEW; SACCADIC EYE MOVEMENT; SENSORIMOTOR NEUROPATHY; SEXUAL DYSFUNCTION; SLEEP DISORDER; SPINOCEREBELLAR ATAXIA TYPE 2; SPINOCEREBELLAR DEGENERATION; TREMOR; TUNISIA; URINARY DYSFUNCTION; VOLUNTARY MOVEMENT; ZINC DEFICIENCY;

EID: 84861120199     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000212Y.0000000005     Document Type: Review

References (55)

1. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet 2004;3:291-304.
2. Velázquez PL, Santos FN, García ZR, Paneque HM, Hechevarria RR. Epidemiology of Cuban hereditary ataxia. Rev Neurol 2001;32:606-11.
3. Velázquez-Pérez L, Rodríguez-Labrada R, Canales-Ochoa N, Sánchez-Cruz G, Fernández-Ruiz J, Medrano J, et al. Progression markers of spinocerebellar ataxia 2. A twenty years neurophysiological follow up study. J Neurol Sci 2010; 290:22-6.
4. Velásquez Pérez L, Almaguer Mederos L, Santos Falcón N, Hechavarria R, Sánchez Cruz G, Paneque HM. Spinocerebellar ataxia type 2 in Cuba. A study of the electrophysiological phenotype and its correlation with clinical and molecular variables. Rev Neurol 2001;33(12):1129-36.
5. Orozco DG, Estrada R, Perry T, Araña J, Fernández R. Dominantly inherited olivopontocerebellar atrophy from eastern Cuba. Clinical, neuropathological and biochemical findings. J Neurol Sci 1989;93:37-50.
6. Pandolfo M. Drug insight: antioxidant therapy in inherited ataxias. Nat Clin Pract Neurol 2008;4(2):86-96.
7. Diplock AT. Antioxidant and disease prevention. Mol Asp Med 1994;15:293-376.
8. Harding AE. Clinical features and classification of inherited ataxias. In: Harding AE, Deufel T, (eds.) Inherited ataxias. New York: Raven; 1993. vol. 61. p. 1-14.
9. Wadia N, Pang J, Desai J, Mankodi A, Desai M, Chamberlain S. A clinicogenetic analysis of six Indian spinocerebellar ataxia (SCA2) pedigrees. Brain 1998;121:2341-55.
10. Perretti A, Santoro L, Lanzillo B. Autosomal dominant cerebella ataxia type I: multimodal electrophysiological study and comparison between SCA1 and SCA2 patients. J Neurol Sci 1996; 142:45-53.
11. Estrada R, Galárraga J, Orozco G, Nodarse A, Auburger G. Spinocerebellar ataxia 2 (SCA2):morphometric analyses in 11 autopsies. Acta Neuropathol 1999;97:306-10.
12. Lastres-Becker I, Rub U, Auburger G. Spinocerebellar ataxia 2 (SCA2). Cerebellum 2008;7(2):115-24.
13. Velazquez-Perez L, Seifried C, Santos-Falcon N, Abele M. Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol. 2004;56(3):444-7.
14. Sahnoun Z, Jamoussi K, Zeghal KM. Free radicals and antioxidants: human physiology, pathology and therapeutics aspects. Therapy 1997;52(4):251-70.
15. Nonia D, Schmidt MH, van de Loo S, Eich F, Dikic I, Nowock J, et al. Ataxin 2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell Signal 2008;20:1725-39.
16. Velazquez Perez L, Sanchez Cruz G, Canales Ochoa N, Rodriguez Labrada R. Electrophysiological features in patients and presymptomatic relatives with spinocerebellar ataxia type 2. J Neurol Sci 2007;263(1-2):158-64.
17. Rub U, Del Turco D, Burk K. Extended pathoanatomical studies point to a consistent affection of the thalamus in spinocerebellar ataxia type 2. Neuropathol Appl Neurobiol 2005;31: 127-40.
18. Maher P. Redox control of neural function: Background, mechanism, and significance. Ant Redox Signal 2006;8:1941-70.
19. Rao Muralikrishna R, Hatcher JF. Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. Ant Redox Signal 2010;12(1):125-69.
20. Carlson KM, Andersen JM, Orr TH. Emerging pathogenic pathways in the spinocerebellar ataxias. Curr Opin Genet Dev 2009;19:247-53.
21. Lloret A, Calzone R, Dunster C, Manini P, d'Ischia M, Degan P, et al. Different patterns of in vivo prooxidant states in a set of cancer or aging related genetic diseases. Free Rad Biol Med 2008;44:495-503.
22. Satterfield TF, Pallanck LJ. Ataxin 2 and its drosophila homolog ATX-2 physically assemble with polyribosomes. Hum Mol Genet 2006;15:2523-32.
23. Raiser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsh S. An integrative approach to gain insights into the cellular function of human ataxin 2. J Mol Biol 2005;346:203-14.
24. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39: 44-84.
25. Casetta V, Govoni, Granieri E. Oxidative stress, antioxidants and neurodegenerative diseases. Curr Pharm Des 2005;11:1-20 I.
26. Grisham MB, McCord JM. Chemistry and cytotoxicity of reactive oxygen metabolites. In: Taylor AE, Matalon S, Ward P, (eds.). Physiology of oxygen radicals. Bethesda, Maryland, American Physiological Society, Clinical Physiology Series Book, 316 pages, 1986. p. 1-18.
27. Southorn PA, Powis G. Free radicals in medicine I. Chemical nature and biologic reactions. Clin Proc 1988;63:381-9.
28. Matilla-Dueñas A, Sánchez I, Corral-Juan M, Dávalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum 2010;9:148-66.
29. Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 is not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 2000; 26:44-50.
30. Aguiar J, Fernández J, Aguilar A, Mendoza Y, Vázquez M, Suárezd J, et al. Ubiquiyuos expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice. Neurosci Lett 2006;392:202-6.
31. Albrecht M, Golatta M, Wullner U, Lengauer T. Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem 2004;271:3155-70.
32. Boesch SM, Schocke M, Burk K, Hollosi P, Fornai F, Aichner FT, et al. Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia 2 and 6. J Magn Reson Imaging 2001;13:553-9.
33. Boesch SM, Wolf C, Seppi K, Felber S, Wenning GK, Schocke M. Differentiation of SCA 2 from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging 2007;25(3):564-9.
34. Oz G, Hutter D, Tlac I, Clark B, Gross MD, Jiang H, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord 2010;25(9): 1253-61.
35. Oz G, Iltis I, Hutter D, Thomas W, Busara KO, Gomez CM. Distinct neurochemical profiles of spinocerebellar ataxias 1,2,6 and cerbellar system atrophy. Cerebellum 2011;10(2):208-17.
36. Almaguer L, Almaguer D, Gonzáles Y, Martínez E, Valcárcel P. Capacidad antioxidante total de en pacientes cubanos con ataxia Espinocerebelosa tipo 2. Rev Mex Neuroci. 2005;6(3):201-6.
37. Velázquez L, Sánchez G, García JC, Delgado R, Márquez L, Martínez E, et al. Spinocerebellar ataxia type 2 (sca-2) in Cuba. A study of the clinical electrophysiological and redox system variations and its correlation with CAG repeats. Rest Neurol Neurosci. 2003;20(6):277.
38. Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AI. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 2008;15(12):1371-9.
39. Rustin P, Rotig A, Munnich A, Siddi D. Heart hypertrophy and function are improved by idebonone in Friderich's ataxia. Free Radic Res 2002;36:467-9.
40. Mariotti AO, Solari A, Torta D, Marano L, Fiorentini C, Di D. Idebenone treatment in Friedreich's Ataxia: one-year-long randomize placebo-controlled trial. Neurology 2003;60(10):1676-9.
41. Di Prospero NA, Baker A, Jeffries N, Fischebeck KH. Neurological effect of high-dose idebenone in patients with Friedreich's Ataxia: a randomize placebo-controlled trial. Lancet Neurol 2007;6(10):878-86.
42. Pineda M, Arpa J, Montero R, Aracil A, Dominguez F, Galvan M, et al. Idebenone treatment in paediatric and adult patients with Friedreich's Ataxia: long-term follow-up. Eur Paediatr Neurol 2008;12(6):470-5.
43. Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005;62:621-6.
44. Reichenbach J, Schubert R, Schindler D, Muller K, Bohles HJ, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal 2002;4:465-9.
45. Gatei M, Shkedy D, Khanna KK, Uziel T, Shiloh Y, Pandita TK. Ataxia telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid. Oncogene 2001;20: 289-94.
46. Aksoy Y, Sanal O, Metin A, Tezcan I, Ersoy F, Ogus H, et al. Antioxidant enzymes in red blood cells and lymphocytes of ataxia telangiectasia patients. Turk J Pedriatr 2004; 46:204-7.
47. Marcelain K, Navarrete CL, Barvo M, Santos M, Be C, Pincheira J. Effect of vitamin E (DL alpha tocoperol) on the frequency of chromosomal damage in lymphocytes from patients with ataxia telangiectasia. Rev Med Chil 2002;130:957-63.
48. Browse SE, Roberts LJ, II, Dennery PA, Doctrow SR, Beal MF, Barlow C, et al. Treatment with catalytic antioxidant corrects the neurobehavioral defect in ataxia telangiectasia mice. Free Rad Biol Med 2004;36:938-42.
49. Reliene R, Fischer E, Schiest RH. Effects of N acetylcysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res 2004;64:5148-53.
50. Schubert R, Erker L, Barlow C, Yakushiji H, Larson D, Russo A, et al. Cancer chemoprevention by the antioxidant Tempol in atm-deficient mice. Hum Mol Genet 2004;13:1793-802.
51. Velázquez-Pérez L, Rodríguez-Labrada R, García-Rodríguez JC, Almaguer-Mederos LE, Cruz-Mariño T, Laffita-Mesa JM. A comprehensive review of spinocerebellar ataxia type 2 in Cuba. Cerebellum 2011;10:184-98.
52. Soong B, Paulson HL. Spinocerebellar ataxias: an update. Curr Opin Neurbiol 2007;20:438-46.
53. Calabrese V, Guagliano E, Sapienza M, Mancuso C, Butterfield DA, Stella AM. Redox regulation of cellular stress response in neurodegenerative disorders. Ital J Biochem 2006;55(3-4): 263-82.
54. Yokota T, Igarashi K, Uchihara T, Jishage K, Tomita H, Inaba A, et al. Delayed-onset ataxia in mice lacking α-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. PNAS. 2001;98(26):15185.
55. Velásquez-Pérez L, Rodríguez-Chanfrau J, García-Rodríguez JC, Sánchez-Cruz G, Aguilera-Rodríguez R, Rodríguez-Labrada R, et al. Oral zinc sulphate supplementation for six months in SCA2 patients: a randomized, double-blind, placebo-controlled trial. Neurochem Res 2011;36:1793-800.